NCT06399640 - Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 14, 2024

Primary Completion Date

February 1, 2027

Study Completion Date

October 1, 2027

Conditions

Relapsed Myelodysplastic SyndromeRefractory Myelodysplastic SyndromeAcute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia

Interventions

DRUG

Eltanexor

Eltanexor will be taken by mouth

DRUG

Venetoclax

Venetoclax will be taken by mouth

PROCEDURE

Bone Marrow Aspiration and Biopsy

Undergo bone marrow aspiration and biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

Trial Locations (1)

37203

RECRUITING

Vanderbilt University/Ingram Cancer Center, Nashville